- Home
- ARVN vs GPRE Comparison
ARVN vs GPRE Comparison
Compare ARVN & GPRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | GPRE |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 812.2M |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ARVN | GPRE |
|---|---|---|
| Price | $10.92 | $15.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 8 |
| Target Price | ★ $15.05 | $11.31 |
| AVG Volume (30 Days) | 781.8K | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $262,600,000.00 | ★ $2,091,680,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.90 | $3.14 |
| 52 Week High | $14.22 | $17.94 |
Technical Indicators
Market Signals| Indicator | ARVN | GPRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 53.08 |
| Support Level | $9.02 | $14.84 |
| Resistance Level | $12.43 | $16.80 |
| Average True Range (ATR) | 0.63 | 0.91 |
| MACD | 0.07 | -0.16 |
| Stochastic Oscillator | 44.71 | 39.32 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.